Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.

The Lancet. Oncology - 1 Jan 2022

Naranbhai Vivek, Viard Mathias, Dean Michael, Groha Stefan, Braun David A, Labaki Chris, Shukla Sachet A, Yuki Yuko, Shah Parantu, Chin Kevin, Wind-Rotolo Megan, Mu Xinmeng Jasmine, Robbins Paul B, Gusev Alexander, Choueiri Toni K, Gulley James L, Carrington Mary

Abstract excerpt

BACKGROUND: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci could differentially affect the response to ICIs. The aim of this epidemiological study was to determine the effect of HLA-A*03 as a biomarker for predicting response to immunotherapy. METHODS: In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epidemiologic Studies

Share to HLA-A3 Antigen

Share to Immune Checkpoint Inhibitors

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34895481
DOI: 10.1016/S1470-2045(21)00582-9
PMCID: PMC8742225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.PMID 34895481Read ↗

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity Read ↗

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.Semantic proximity Read ↗

Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.Semantic proximity Read ↗

Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.Semantic proximity Read ↗

Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response.Semantic proximity Read ↗

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.Semantic proximity Read ↗

Defining the genetic determinants of CD8 <sup>+</sup> T cell receptor repertoire in the context of immune checkpoint blockadeSemantic proximity Read ↗

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read ↗

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Semantic proximity Read ↗

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisSemantic proximity Read ↗

Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.